Healthcare Services

Expansion of immunization programs and improved vaccine access are driving growth in the live attenuated polio vaccine market

April 23, 2026April 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Live Attenuated Polio Vaccine Market Over The 2026–2030 Period?

The live attenuated polio vaccine market has experienced significant expansion in recent years. Its valuation is anticipated to climb from $1.98 billion in 2025 to $2.13 billion in 2026, driven by a compound annual growth rate (CAGR) of 7.6%. This historical upward trend can be ascribed to global initiatives aimed at polio eradication, the broad acceptance of oral polio vaccines, robust immunization programs led by governments, early effectiveness in reducing polio transmission, and assistance from international health organizations.

The live attenuated polio vaccine market is poised for substantial expansion over the next few years. It is projected to achieve a value of $2.85 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period stems from ongoing eradication endeavors in remaining endemic regions, an intensified focus on preventing outbreaks, the expansion of vaccination coverage into underserved populations, increased financial backing for public health immunization programs, and a growing emphasis on vaccine accessibility and affordability. Significant trends for the forecast period include the sustained use of oral polio vaccines in mass immunization drives, a strong emphasis on achieving community-level immunity and controlling transmission, persistent demand in polio-endemic and high-risk regions, the integration of live attenuated polio vaccine into national immunization programs, and a focus on ensuring long-lasting immunity in pediatric vaccinations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24280&type=smp

What Factors Are Contributing To The Growth Of The Live Attenuated Polio Vaccine Market?

Future growth in the live attenuated polio vaccine market is anticipated to be driven by the increasing reach of immunization programs. Immunization programs represent structured initiatives undertaken by governmental bodies, health agencies, or other organizations to administer vaccines to communities, thereby curbing the spread of contagious diseases. This expansion stems mainly from heightened global understanding of the significance of disease prevention, coupled with robust backing from governments, international health organizations, and financial sponsors. These programs bolster the live attenuated polio vaccine (LAPV) through guaranteeing extensive distribution, secure delivery, and broad coverage, which helps establish herd immunity, hinders virus transmission, and contributes to worldwide polio eradication efforts. As an illustration, the UK Health Security Agency, a government entity based in the UK, reported in May 2025 that during the 2023–2024 season, a school-based initiative in England aimed at all children aged 4 to 16 years (Reception to Year 11) resulted in 52.2% of eligible children from Reception to Year 9 (3,498,576 out of 6,708,016) receiving the vaccine. This figure marks a minor increase compared to the 51.9% coverage (3,502,566 out of 6,747,523) observed during the 2022–2023 season. Consequently, the increased reach of immunization programs is propelling the growth of the live attenuated polio vaccine market.

What Segment Categories Shape The Live Attenuated Polio Vaccine Market Segment Landscape?

The live attenuated polio vaccine market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Bivalent, Trivalent

2) By Age Group: Infants (0-1 years), Children (1-5 years)

3) By End-User: Clinics, Public Health Agencies, Other End-Users

Subsegments:

1) By Monovalent: mOPV1 For Serotype 1

2) By Bivalent: Type 1, Type 3

3) By Trivalent: Poliovirus Type 1, Poliovirus Type 2, Poliovirus Type 3

What Trends Are Shaping The Future Of The Live Attenuated Polio Vaccine Market?

Leading firms in the live attenuated polio vaccine market prioritize securing regulatory authorizations to ensure their vaccines comply with global health authorities’ safety and effectiveness benchmarks. Such approvals denote the official permission issued by governmental health agencies or oversight entities, enabling a product, like a vaccine, to be commercialized, distributed, and utilized within a particular territory or nation. An example is in July 2024, when Biological E, an India-based pharmaceutical and biologics company, gained World Health Organization (WHO) approval for its novel oral polio vaccine type 2 (nOPV2). This next-generation live, attenuated oral vaccine is specifically engineered to overcome issues linked with conventional oral polio vaccines. More effectively than its forerunner, this advanced vaccine is intended to counteract circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. nOPV2 features improved genetic stability, thereby mitigating the chance of the vaccine virus reverting to a virulent state, a concern previously associated with earlier vaccines.

Who Are The Companies Operating Across The Live Attenuated Polio Vaccine Market Value Chain?

Major companies operating in the live attenuated polio vaccine market are Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Biological E Limited, Indian Immunologicals Limited, Bharat Biotech International Limited, Panacea Biotec, Haffkine Biopharmaceutical, Bio Farma, Bilthoven Bio, Vabiotech, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., LG Chem Ltd., Chumakov Federal Scientific Center, Institute of Poliomyelitis and Viral Encephalitides, Statens Serum Institut, Federal State Unitary Enterprise Microgen, Pasteur Institute of Iran, Institut Pasteur de Dakar

Get The Full Live Attenuated Polio Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/live-attenuated-polio-vaccine-global-market-report

Which Region Is The Largest In The Live Attenuated Polio Vaccine Market?

North America was the largest region in the live attenuated polio vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated polio vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Live Attenuated Polio Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/live-attenuated-polio-vaccine-global-market-report

Browse Through More Reports Similar to the Global Live Attenuated Polio Vaccine Market 2026, By The Business Research Company

Conjugate Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Inactivated Vaccines Market Report

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795